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Abstract
Background: Parkinson’s disease (PD) is a chronic, progressive neurological disorder with many intractable
consequences for patients and their family caregivers. Little is known about the possibilities that palliative care
could offer to patients and their proxies. Guidelines strongly recommend palliative care to improve the quality of
life and – if needed – the quality of dying. However, providing palliative care to persons with PD involves specific
challenges. For example, a timely initiation of palliative interventions is difficult because due to the gradually
progressive nature of PD, there is often no clear marker for the transition from curative towards palliative care.
Furthermore, there is little evidence to indicate which palliative care interventions are effective. Here, we describe
the contours of a study that aims to examine the experiences of patients, (bereaved) family caregivers and
professionals, with the aim of improving our knowledge about palliative care needs in PD.
Methods/design: We will perform a mixed methods study to evaluate the experiences of patients, (bereaved) family
caregivers and palliative care professionals. In this study, we focus on Quality of Life, Quality of Care, perceived
symptoms, caregiver burden and collaboration between professionals. In phase 1, we will retrospectively explore
the views of bereaved family caregivers and professionals by conducting individual interviews and focus group
interviews. In phase 2, 5–15 patients with PD and their family caregiver will be followed prospectively for 8–12 months.
Data collection will involve semi-structured interviews and questionnaires at three consecutive contact moments.
Qualitative data will be audio recorded, transcribed and analyzed using CAQDAS. If patients pass away during the
study period, a bereavement interview will be done with the closest family caregiver.
Discussion: This study will offer a broad perspective on palliative care, and the results can be used to inform a palliative
care protocol for patients with PD. By describing the experiences of patients, (bereaved) family caregivers and
professionals with palliative care, this investigation will also establish an important ground for future
intervention research.
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Background
Parkinson’s disease (PD) is a common neurodegenerative
disorder, affecting approximately 1% of the population
over the age of 65 in Western countries [1]. PD is an in-
curable disease, and treatment exists of symptomatic
strategies (such as suppressing symptoms, or offering
support). As PD progresses, patients can experience a
wide range of symptoms like immobility, pain, fatigue,
sleeping problems, cognitive deficits and dementia [2–
4]. A nursing home admission is inevitable in 20–40% of
PD patients [5–9]. Disease management in advanced
stages of PD becomes increasingly difficult, whereas the
emphasis on quality of life becomes more important. Pa-
tients with PD experience considerable discomfort at the
end of life; in fact, their symptom burden is comparable
to that of advanced cancer patients [2, 10].
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Palliative care is “an approach that improves the
quality-of-life of patients and their families facing prob-
lems associated with life-threatening illness, through the
prevention and relief of suffering by means of early iden-
tification and impeccable assessment and treatment of
pain and other problems, physical, psychosocial and
spiritual” [11]. However, there is barely any knowledge
about the effective and useful components for palliative
care in PD. [12] Hasson et al. reviewed the current evi-
dence and reported several challenges that may occur in
clinical practice. Problematic is the (timely) identifica-
tion of PD patients and their palliative care needs. The
absence of a concrete starting point for focusing on pal-
liative care needs makes it difficult to identify palliative
care needs during the disease course.
A few specific disease symptoms have been recognized
as indicators for palliative care needs. This includes the
first episode of aspiration and the occurrence of key
clinical features such as visual hallucinations, regular
falls, dementia and admission to residential care; patients
experiencing such symptoms might need special atten-
tion and start of the palliative care phase can be consid-
ered [12, 13]. However, the appearance of these specific
symptoms do not always lead to recognition of palliative
care needs or referral to palliative care services.
PD patients and family caregivers described a lack of
knowledge about palliative care services [14]. And if they
had received care from a palliative care service, then co-
ordination of care was reported to be poor [14–16].
Studies conclude that family caregivers often feel alone
in the care for the patient with advanced PD [14]. Only
few PD patients and family caregivers receive palliative
care in contrast to patients with malignant diseases [17].
Most studies evaluated patients with PD needs in early
stages and paid less attention to patients with advanced
PD [18, 19]. However, a few studies found unmet needs
in advanced PD [20] Patients with advanced PD are
cared for by family members, usually older spouses [21].
Schrag et al. reported that for patients at advanced
stages, caregiver burden rises with increasing disability,
and also with the appearance of symptoms such as hallu-
cinations, depression and falls [22]. Family caregivers of
patients with advanced PD reported considerable
changes in their life [14, 15, 20, 21, 23]. More specific-
ally, spouses felt that their primary role in the relation-
ship changed, due to cognitive deficits and speech
problems of the patients. Family caregivers struggled
with caring for their loved ones as long as possible and
specifically with the point of admission to a nursing
home. Studies also reported that family caregivers had
fewer social contacts and opportunities to socialize, had
a reduced financial income and tended to experience
poorer health; this is particularly related to features of
late stage PD [21, 22]. Likewise Carter et al. explored
pre-death grief in family caregivers of advanced PD
patients and the results suggests that pre-death grief was
a significant finding in family caregivers and was more
associated with the presence of patient’s cognitive
decline [24].
Four studies reported professionals’ experiences with
(the concept of) palliative care and PD [25–28]. Wal-
dron et al. showed that professionals often misconceive
the putative value of rehabilitation in the palliative care
phase. Moreover, professionals felt unsure about the care
they delivered in this phase. Several studies reported that
professionals experienced a lack of education and com-
petence in this field. Furthermore, the collaboration be-
tween palliative care services and more general
professionals was missed. Perceived barriers in the
collaboration were inadequate referral and lack of
communication.
In order to address the existing knowledge gap, we will
now launch the ParkinsonSupport study, with the aim of
identifying the experiences with end of life issues among
both people with PD, their family caregivers and the pro-
fessionals involved. Part of this project is a qualitative
after-death study with professionals and beraeved family
caregivers, as well as a prospective multiple case study
with patients and their family caregivers.
These issues will be explored by asking patients,
(bereaved) family caregivers and professionals about
their experiences and ideas about optimizing palliative
care. Important aspects of this exploration also include
identifying terminal care strategies that have already
been used in practice by professionals, and the identifi-
cation of ‘red flags’ in order to get more insight informa-
tion to start palliative care interventions timely.
Additional questions emerging from our main research
question include: [1] What opinions do patients,
(bereaved) family caregivers and professionals have
about the quality of care provided? [2] What are specific
disease symptoms that may assist in the timely identifi-
cation of palliative care needs in patients with advanced
PD? [3] How do disease care needs progress over
8-12 months in PD patients and family caregivers? [4]
What are the major decisions and symptoms in dying
with Parkinson disease?
The objective of this paper is to provide a detailed
description of the study design and research protocol.
Methods/study design
This study includes two parts. We will start with an
explorative, qualitative after-death study. In-depth indi-
vidual and focus group interviews with bereaved family
caregivers and professionals involved in the care for
people with PD will be held. The second part consists of
a qualitative prospective multiple case study design [29].
This design facilities the understanding of circumstances
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and experiences of patients with advanced PD and their
family caregivers.
Explorative after-death study
A topic list will be developed based on a literature study.
A pre-test will be held in a test panel to ensure compre-
hensibility and completeness of the topic guide. Subse-
quently, 10 professionals coming from different
disciplines and 10 bereaved family caregivers will be
interviewed. Also, focus group interviews will be held
with professionals until saturation is reached. This de-
sign allows for obtaining in-depth information about the
needs of bereaved family caregivers of patients with
advanced PD and professionals.
Multiple-case study
Patients and their family caregivers will be involved in
the multiple-case study. We will follow around 5 to 15
PD patients (and if present one family caregiver per pa-
tient) to address how quality of life and quality of care is
being perceived and any changes over 8 to 12 months.
PD patients will be included based on an affirmative an-
swer from the attending physician on the so-called
“surprise question”: ‘Would I be surprised if this patient
died in the next 12 months?’ [30]. Patients will be visited
at home at baseline, at 6 months and at 12 months after
baseline to assess experiences, symptoms, quality of life
and quality of care. Data will be collected by in-depth in-
terviews with the PD patient as well as his/her family
caregiver. Alongside the interviews, questionnaires and
documents (e.g. medical records) will be used. If patients
die during the study period, the closest family caregiver
will be invited for a bereavement interview.
Selection of participants
We will recruit professionals via the Dutch Parkinson-
Net, a professional Parkinson-specific healthcare net-
work with full nationwide coverage, consisting of 69
regional networks with more than 3000 professionals
specialized in the treatment of patients with PD, includ-
ing groups of specifically trained neurologists, PD nurse
specialists and nursing home physicians [31, 32]. We
also include bereaved family caregivers via a partnership
with the Dutch Parkinson Patient Association, and via
the web-based community for PD patients and families
(www.parkinsonconnect.nl). For the case study, we will
identify patients in advanced stages in hospitals, general
practices and nursing homes. We will ask neurologists,
PD nurse specialists and elderly care physicians who are
member of ParkinsonNet to screen their population.
Signed informed consent forms from the patient and
family caregiver will be obtained before study entry.
Explorative after death study
Bereaved family caregivers who have been involved in
the care for a patient with advanced PD during the past
two years, will be invited for an individual interview. We
aim to conduct 10 individual interviews. We also aim for
a diversity of professional disciplines in the interviews,
as the care for PD is multi-professional. Focus groups
will be heterogeneous. Participants need to meet the in-
clusion criteria (see “Inclusion criteria for bereaved fam-
ily caregivers and professionals”) in order to be eligible
for participation.
Inclusion criteria bereaved family caregivers
1. 18 years or above;
2. cognitively able to participate in interviews;
3. bereaved family caregiver who has been involved in
the care for a patient with advanced PD over the last
2 years.
Inclusion criteria professionals
1. Professionals who were involved in the care for a
patient with advanced PD over the last 2 years.
Multiple-case study
We aim to achieve a total sample of around 5–15 pa-
tients and family caregivers. Patients (and if present one
family caregiver per patient) will be recruited by their at-
tending neurologist, PD nurse specialist or general prac-
titioner. A family caregiver, defined as the person who
non-professionally takes care and supports the patient
for most of the time, will be identified by the patient.
Family caregivers need not necessarily be a family mem-
ber. Participants need to meet the inclusion criteria (see
“Inclusion criteria for patients and family caregivers”) in
order to be eligible to take part in the study. In order to
gain variation in patients’ experiences with care
provision, we strive to purposively recruit patients who
live at different settings e.g. at home or in a nursing
home.
Inclusion criteria patients
1. 18 years or above;
2. Diagnosis of “idiopathic PD” according to UK
Parkinson’s Disease Society Brain Bank clinical
diagnostic criteria;
3. Patients who are suffering from late-stage Parkinson-
ism classified according to Hoehn and Yahr stage
(H&Y) IV or V in the “On”-state; OR who have de-
veloped significant disability (Schwab and England
stage 50% or less) in the “On”-state;
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4. Cognitively able to complete questionnaires and to
participate in interviews;
5. The patient’s attending doctor answers “No” to the
surprise question: “Would you be surprised if the
patient died within the coming 12 months?”
Inclusion criteria family caregivers
1. 18 years or above;
2. Cognitively able to complete questionnaires and to
participate in interviews;
3. Identified by the patient as family caregiver.
Data collection
Explorative after death study
We will start with semi-structured interviews with 10
bereaved family caregivers and 10 professionals. We will
use the COREQ-checklist for reporting qualitative stud-
ies as far as this is applicable to our study. Based on the
literature, a semi-structured interview guide will be de-
veloped for the individual interviews (see Table 1 for
topic areas). Individual interviews will be conducted by
trained researchers from the project team. All interviews
will be audio recorded and transcribed verbatim. Two
researchers undertake the data collection independently
and roughly analyze the transcripts. Focus group inter-
views will be used to obtain further insight into the ex-
periences of the professionals with (their) palliative care,
until saturation is reached. Common and consistent
themes within individual and focus group interviews will
be drawn together in the final content analysis.
Multiple-case study
The multiple case study consists of three consecutive con-
tact moments with patients and family caregivers with an
interval of approximately 6 months (baseline, month 6,
month 12). During a home visit, we will conduct semi-
structured interviews and complete questionnaires. We
will use a questionnaire with Parkinson-specific supple-
ments; the Edmonton Symptom Assessment System Scale
modified for Parkinson disease (ESAS-PD) [33]. Socio-
demographic data; age, gender, marital status, education,
employment status, and relationship between patient and
family caregiver, will be collected at baseline.
At each contact moment, we will also separately inter-
view the family caregiver at home. Family caregivers may
feel uncomfortable in the precense of their partner to
speak about the impact of advanced PD, patients’ mental
health status or caregiver burden. The data collection
methods that will be applied to assess the outcome pa-
rameters are described in Table 2 for the case study. If a
patient dies during the study period, a bereavement
interview will be done with the family caregiver.
We will ask patients if they want the presence of a
family caregiver during the interview. Patients with PD
in an advanced stage are vulnerable and may have speak-
ing problems. Therefore, we expect that patients want to
be supported by their family caregiver. If this is the case,
we will, in order to minimize influences of opinions be-
tween patients and family caregivers, emphasize the role
of translator for the family caregiver in the interview
with the patient.
Questionnaires
Questionnaires were selected based on: validity and/or
applicability in patients with PD and/or palliative care,
time needed for completion, and available translations
into Dutch. Patient’s disease severity and the ability of
independent living will be measured with Hoehn and
Yahr (H&Y) scale and Schwab & England [34, 35].
Edmonton symptom assessment scale Parkinson disease
(ESAS-PD)
The Edmonton Symptom Assessment Scale Parkinson
Disease will be filled in by patients and family caregivers
to measure perceived disease symptoms of patients [33].
It is tested but limitedly used in palliative care for pa-
tients with Parkinson Disease in contrast to the original
ESAS which is widely used, tested and validated. The
completion time is short, approximately 7 min and the
ESAS-PD is available in Dutch [36].
Table 1 Interview topic areas for individual interviews
Bereaved family caregiver Professionals
Demographic data: age, gender, years of caring Demographic data: age, gender, profession, years of experience,
highest level of education
- History of family member’s illness
- Exploration of problems and needs of the patient during advanced PD and
end of life phase (palliatieve care domains: physical, psychosocial, mental
and spiritual)
- Exploration of problems and unmet and met needs of the bereaved family
caregiver (palliative care domains: physical, psychosocial and spiritual)
- Problems and needs in the dying phase (including end of life decisions)
- Exploration of the collaboration between professionals and access to
palliative care services
- Bereavement support
- Defining palliative care
- Perceptions of patients’ and carers’ palliative care needs
- Barriers and facilitators in providing palliative care
- Exploration of ethical issues and end of life decisions
- Exploration of the collaboration between professionals and
palliative care services
- Expectations and/or future improvements
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Zarit burden interview (ZBI)
The Zarit burden Interview will be used with family
caregivers to measure their perceived burden [37]. The
ZBI is widely used and extensively tested, also in studies
with PD patient caregivers. It has been translated into
Dutch and has a completion time of approximately
10 min.
Parkinson disease questionnaire 8 (PDQ-8)
The Parkinson’s Disease Questionnaire 8 is a disease-
specific instrument that captures PD patients’ perception
of their illness. The PDQ-8 covers eight dimensions of
ill-health, and contains 8 questions. PDQ-8 is a shorter
version of the PDQ-39, which is widely tested and vali-
dated. The PDQ-8 has been used in varies studies with
good psychometric results [38–40].
Functional assessment of cancer therapy – General (FACT-G
version 4)
FACT-G will be used to assess the patients’ functional
status. The instrument is used and validated in mainly
patients with cancer and a small group of patients with
chronic diseases. The FACT-G is a self rating question-
naire, which contains questions about the patient’s own
ability of functioning at four subscales (physical well-
being, social wellbeing, emotional wellbeing and func-
tional wellbeing) [41]. It has been translated into Dutch
and has a completion time of approximately 5-10 min.
The expected duration of the entire study period will
be 24 months, including recruitment, data collection
and analysis. Data collection has started in September
2016 and will finish in September 2018.
Data management and analysis
We will analyze data from individual interviews and
focus group interviews using a thematic content analysis
approach. Individual- and focus group interviews will be
tape recorded and transcribed verbatim. Two researchers
will collect the data and will independently analyze
transcripts and build a codebook. The codebook allows
for comparison and contrasting between interpretations,
helping to enhance inter-rater reliability. Common and
consistent themes will be drawn together in the analysis.
Transcriptions will be analyzed using content analysis
techniques supported by a qualitative analysis software
package (CAQDAS).
Interviews will be analyzed in cases and by means of
the same iterative procedure as described above. During
this analytical phase, we will integrate the quantitative
variables and qualitative findings so as to draw a more
complete picture of the experiences in the end of life of
people with PD and their family caregivers.
Ethical issues
Sensitive one-to-one interviews will be performed with
PD patients with minimized risk of any harm, distress or
inconvenience to participants. Ethical approval was re-
ceived from the ethics committee Arnhem-Nijmegen
[number; 2016–2424] in February 2017. In order to
minimize the burden of data collection during the mul-
tiple case study, questionnaires have a short completion
time and the total duration of interviews will be limited
to a maximum of 45 min. The interview will be inter-
rupted if a PD patient has an ‘off-phase’ and will con-
tinue later on or scheduled another day. Interviews will
be conducted by researchers who have experience in the
care for advanced PD patients/family caregivers and
qualitative research.
We expect that PD patients in our study may have
cognitive deficits or develop dementia during the study.
We expect most patients to be cognitively able to com-
prehend the aims, but we will evaluate participation if
patients show signs of dementia and are unable to
complete questionnaires or participate in interviews.
Discussion
Current knowledge about palliative care in PD is scarce.
This study is the first multifaceted and mixed-methods
Table 2 Data collection schedule
Outcome parameter Data collection method T0 T1 T2
Patient
Disease severity, perceived symptoms ESAS-PD X X X
Hoehn & Yahr, Schwab & England X X X
Functional Assessment FACT-G X X X
Experiences with palliative care, Quality of Care Semi-structured interview X X X
Quality of Life PDQ 8 X X X
Family caregiver
Experiences with palliative care, Quality of Care Semi-structured interview X X X
Perceived symptoms of patient ESAS-PD X X X
Caregiver Burden ZBI X X X
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study that will provide valuable knowledge about the ex-
periences of patients, family caregivers, bereaved family
caregivers and professionals. The results can be used to
directly improve patient care, and to improve policy de-
cisions on PD palliative care. Furthermore, we will use
the input from this study to inform a future intervention
study in advanced PD.
The recruitment of professionals in studies can be
problematic. A strength of this study is the presence of
the national ParkinsonNet infrastructure within the
Netherlands. [31, 32] Therefore, we have easier access to
professionals who work regularly with PD patients’ in
the end of life. ParkinsonNet give us the opportunity to
readily find the various relevant professional disciplines.
Furthermore, the infrastructure of ParkinsonNet will
help us to find PD patients and bereaved family care-
givers through contacts with professionals.
The multiple-case study design allows for an in-depth
and longitudinal exploration of the palliative care trajec-
tory of PD patients and family caregivers. The prospect-
ive design allows us to gain insight in needs and burden
change over time. Identifying patients at the end of life
will be a challenge. We use the “surprise question” but
we do not know if this question is appropriate in PD.
[12] By using the “surprise question” we might identify
patients who still have a life expectancy longer than
12 months or those with a very short life expectancy of a
couple of weeks. However, there is no evidence based in-
strument or point of access to identify the end of life.
This motivated our choice for additional inclusion criteria
next to the surprise question. We follow PD patients and
their family caregivers for 12 months, assuming this is suf-
ficient to also capture the terminal phase. A small sample
of around 5–15 PD patients and their family caregivers
will be included. This small sample size and heterogeneity
of the PD population may lead to diversity in characteris-
tics of PD patients and their family caregivers. This might
lead to a broad insight in perspectives of the patients
within our sample, which is a strong aspect in qualitative
research. Therefore, we think that this study will gain
more knowledge about the care for patients with advanced
PD. This knowledge will be used for several purposes: to
develop a new multidisciplinary guideline for professionals
working with patients with PD; to create specific informa-
tion materials (e.g. film, leaflet) for patients and caregivers;
and to mutually inform and connect the existing networks
of professional caregivers coming from Parkinson care
and palliative care.
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